Table 1 Baseline demographic and clinical characteristics of registry MDR-TB patients in South Africa
Characteristic, n (%), unless stated otherwise | Bedaquiline N = 3747 | No bedaquiline N = 2234 | Total N = 5981 |
|---|---|---|---|
Mean age, years (SD) | 37.6 (11.9) | 34.2 (14.5) | 36.3 (13.0) |
Age category, years | Â | Â | Â |
 < 12 | 2 (0.1) | 159 (7.1) | 161 (2.7) |
 12–17 | 111 (3.0) | 69 (3.1) | 180 (3.0) |
 ≥ 18–64 | 3549 (94.7) | 1955 (87.6) | 5504 (92.1) |
 ≥ 65 | 84 (2.2) | 49 (2.2) | 133 (2.2) |
Sex | Â | Â | Â |
 Male | 2104 (56.2) | 1254 (56.1) | 3358 (56.1) |
 Female | 1643 (43.8) | 980 (43.9) | 2623 (43.9) |
Resistance category | Â | Â | Â |
 MDR-TB | 1526 (40.7) | 1801 (80.6) | 3327 (55.6) |
 Pre-XDR-TB | 1039 (27.7) | 212 (9.5) | 1251 (20.9) |
 XDR-TB | 1182 (31.5) | 221 (9.9) | 1403 (23.5) |
Patient treatment category | Â | Â | Â |
 New | 1419 (37.9) | 1015 (45.4) | 2434 (40.7) |
 Relapsed | 1216 (32.5) | 703 (31.5) | 1919 (32.1) |
 Treatment after loss to follow-up | 366 (9.8) | 258 (11.5) | 624 (10.4) |
 Treatment after failure 1st line drugsa | 224 (6.0) | 124 (5.6) | 348 (5.8) |
 Treatment after failure 2nd line drugs | 467 (12.5) | 101 (4.5) | 568 (9.5) |
 Other | 55 (1.5) | 33 (1.5) | 88 (1.5) |
HIV and ARTb | Â | Â | Â |
 HIV negative | 990 (26.4) | 713 (31.9) | 1703 (28.5) |
 HIV positive, not on ART | 1263 (33.7) | 852 (38.1) | 2115 (35.4) |
 HIV positive, on ART | 1491 (39.8) | 665 (29.8) | 2156 (36.0) |
Treatment year | Â | Â | Â |
 2015 | 1004 (26.8) | 1116 (50.0) | 2120 (35.4) |
 2016 | 1465 (39.1) | 856 (38.3) | 2321 (38.8) |
 2017 | 1278 (34.1) | 262 (11.7) | 1540 (25.7) |
Indication for MDR-TB treatmentc | Â | Â | Â |
 Pulmonary TB | 3702 (98.8) | 2180 (97.8) | 5882 (98.3) |
 Extrapulmonary TB | 44 (1.2) | 49 (2.2) | 93 (1.6) |
Evidence of cavitary disease on CXR or CTd | Â | Â | Â |
 Yes | 1074 (31) | 4 (6.3) | 1078 (30.5) |
 No | 2393 (69) | 60 (93.8) | 2453 (69.5) |